Alvespimycin (17-DMAG) HCl

For research use only. Not for use in humans.

目录号:S1142 别名: NSC 707545,BMS 826476 HCl,KOS 1022 中文名称:阿螺旋霉素盐酸盐

Alvespimycin (17-DMAG) HCl Chemical Structure

CAS No. 467214-21-7

Alvespimycin (17-DMAG, NSC 707545, BMS 826476, KOS 1022) HCl是一种有效的HSP90抑制剂,无细胞试验中IC50为62 nM。 Phase 2。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 2351.34 现货
RMB 794.94 现货
RMB 2432.56 现货

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Alvespimycin (17-DMAG) HCl发表文献50篇:

产品安全说明书

HSP (HSP90)抑制剂选择性比较

生物活性

产品描述 Alvespimycin (17-DMAG, NSC 707545, BMS 826476, KOS 1022) HCl是一种有效的HSP90抑制剂,无细胞试验中IC50为62 nM。 Phase 2。
特性 17-DMAG是抗生素Geldanamycin 的合成衍生物,比现有抗生素具有较低的肝毒性,比相似衍生物17-AAG效果和有效性更强。
靶点
HSP90 [1]
(Cell-free assay)
62 nM
体外研究

荧光偏振(FP)为基础的竞争性结合实验中,17-DMAG作用于人类 Hsp90比 17-AAG(IC50 为 119 nM)效果高2倍,IC50为 62 nM。17-DMAG作用于过量表达Hsp90“服务蛋白” Her2的SKBR3和 SKOV3细胞,下调Her2,EC50分别为8 nM和 46 nM, 且诱导 Hsp70,EC50分别为 4 nM和 14 nM,结果产生显著的毒性,GI50分别为 29 nM 和32 nM。[1] 17-DMAG和 Vorinostat 联用,通过显著降低cyclin D1和CDK4, 及c-Myc, c-RAF 和AKT水平,协同诱导培养的MCL细胞和原发性 MCL 细胞凋亡。[3]17-AAG 只有效作用于慢性淋巴细胞白血病 (CLL) 细胞的IKKβ,而17-DMAG 处理,有效导致Hsp90 客户蛋白IKKα 和 IKKβ的消耗,导致 NF-κB p50/p65 DNA结合减少,NF-κB 靶基因转录降低,及caspase依赖性凋亡降低。通过靶向作用于NF-κB 家族,17-DMAG作用于CLL细胞而不是正常T细胞或NK细胞,选择性调节毒性,这种作用存在剂量和时间依赖性。[5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SKBr3 MmDiR5l1d3SxeHnjbZR6KGG|c3H5 MXvDfZRwfG:6aXPpeJkh[WejaX7zeEBUU0K{MzDj[YxteyxiSVO1NF0xNjB{NN88UU4> MlPwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZzNkWzOVQoRjF4MU[1N|U1RC:jPh?=
SKBR3 NVXkZYtQTnWwY4Tpc44h[XO|YYm= MofnWZBz\We3bHH0bY9vKG:oIFjzdFcxKGmwIGPLRnI{KGOnbHzzMEBGSzVyPUCuNFA1|ryPLh?= MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjh3NEC2Okc,OTZ6NUSwOlY9N2F-
SKBR3 MWHGeY5kfGmxbjDhd5NigQ>? M1joSmRm\3KjZHH0bY9vKG:oIFjldlIhcW5iU1vCVlMh[2WubIOsJGVEPTB;MD6wNFjPxE1w Mlr5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ6NUSwOlYoRjF4OEW0NFY3RC:jPh?=
SKOV3 NIjzWGtHfW6ldHnvckBie3OjeR?= MW\VdJJm\3WuYYTpc44hd2ZiSIPwO|AhcW5iU1vPWlMh[2WubIOsJGVEPTB;MD6wNVTPxE1w NHLGXVA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNki1OFA3Pid-MU[4OVQxPjZ:L3G+
SKOV3 MkH5SpVv[3Srb36gZZN{[Xl? MWTE[Ydz[WSjdHnvckBw\iCKZYKyJIlvKFONT2[zJINmdGy|LDDFR|UxRTBwMES2{txONg>? M4jCTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4OEW0NFY3Lz5zNki1OFA3PjxxYU6=
AGS NE\BdJZHfW6ldHnvckBie3OjeR?= MVKxOkBpenN? MX\Jcohq[mm2aX;uJI9nKEiLRkGgZYN1cX[jdHnvckBqdiCqdX3hckBCT1NiY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBpgXCxeHnhMYlv\HWlZXSgcJVkcW[ncnHz[UBmgHC{ZYPzbY9vKGGodHXyJFE3KGi{czDifUBz\XCxcoTldkBie3OjeTygTWM2OD1yLkCzOu69VS5? NGPlfIM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{W4N|k2OCd-MUe1PFM6PTB:L3G+
Hep3B Mn3YSpVv[3Srb36gZZN{[Xl? MWmxOkBpenN? M4rLe2lvcGmkaYTpc44hd2ZiSFnGNUBi[3SrdnH0bY9vKGmwIHj1cYFvKEincEPCJINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiaInwc5hq[S2rbnT1Z4VlKGy3Y3nm[ZJie2ViZYjwdoV{e2mxbjDh[pRmeiBzNjDodpMh[nlicnXwc5J1\XJiYYPzZZktKEmFNUC9NE4xPjIQvF2u NXLidm5WRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe1PFM6PTBpPkG3OVg{QTVyPD;hQi=>
AGS NEPldWxHfW6ldHnvckBie3OjeR?= Mn3jNlQhcHK| M{nONHZq[WKrbHn0fUBw\iCqdX3hckBCT1NiY3XscJMhfW6mZYKgco9zdW:6aXOgZ49v\Gm2aX;ud{Bi\nSncjCyOEBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUG2{txONg>? NFf4XIM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{W4N|k2OCd-MUe1PFM6PTB:L3G+
NCI-H526 MX\GeY5kfGmxbjDhd5NigQ>? MnjlNUB2VQ>? Mo[0NlQhcHK| MUfCbY5lcW6pIHHm[olvcXS7IITvJGhUWDlyIHnuJIh2dWGwIF7DTU1JPTJ4IHPlcIx{KGG2IEGgeW0h[W[2ZYKgNlQhcHK|IHL5JIZtfW:{ZYPj[Y5k\SCyb3zhdol7[XSrb36gZZN{[Xl? NIXlXYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{[wN|U1OCd-MUe2NFM2PDB:L3G+
NCI-H526 MYjGeY5kfGmxbjDhd5NigQ>? MX:xJJVO NEnpVpM6PiCqcoO= NWP4VYtnUW6qaXLpeIlwdiCxZjDIV3A6OC2vZXTpZZRm\CCycn;sbYZmemG2aX;uJI9nKGi3bXHuJG5EUS2KNUK2JINmdGy|IHH0JFEhfU1iYX\0[ZIhQTZiaILzJIJ6KHO3bH\vdohw\GGvaX7lJGIh[XO|YYm= NIHneJc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{[wN|U1OCd-MUe2NFM2PDB:L3G+
AGS NUX2NolZTnWwY4Tpc44h[XO|YYm= MmXTTY5pcWKrdHnvckBw\iCqeYDvfIliNWmwZIXj[YQhUEmIMTDhZ5RqfmG2aX;uJIlvKGi3bXHuJGFIWyClZXzsd{BjgSC{ZYDvdpRmeiCpZX7lJIF{e2G7LDDJR|UxRTBwMECzOu69VS5? M2rDWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6M{W5OlMyLz5zOEO1PVY{OTxxYU6=
HeLa M3mxWWZ2dmO2aX;uJIF{e2G7 M4DMdmlvcGmkaYTpc44hd2ZiVF7GMYFteGijLXnu[JVk\WRiTl[tb4FxeGGEIHHjeIl3[XSrb36gbY4hcHWvYX6gTIVN[SClZXzsd{whUUN3ME2wMlE2|ryPLh?= NYDodXJNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUizOVk3OzFpPkG4N|U6PjNzPD;hQi=>
HeLa M2\lSmN6fG:2b4jpZ4l1gSCjc4PhfS=> MVzDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[WxiKGOnbHzzJIJ6KE2WVDDhd5NigSxiSVO1NF0zNjB4zszNMi=> NXfIUpBsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUizOVk3OzFpPkG4N|U6PjNzPD;hQi=>
AGS M{\Ie2N6fG:2b4jpZ4l1gSCjc4PhfS=> MkTLR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRWdUKGOnbHzzJIJ6KE2WVDDhd5NigSxiSVO1NF0yPs7:TT6= MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDN3OU[zNUc,OTh|NUm2N|E9N2F-
A2058 MlXxR5l1d3SxeHnjbZR6KGG|c3H5 M{n5NmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGEzODV6IHPlcIx{KGK7IF3UWEBie3OjeTygTWM2OD1yLkCwNlHPxE1w NFTRZnU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEmyPVQ5Pid-MUi5Nlk1QDZ:L3G+
MDA-MB-231 NVPHOlZRTnWwY4Tpc44h[XO|YYm= MVLJcohq[mm2aX;uJI9nKEi|cEmwJIlvKGi3bXHuJG1FSS2PQj2yN|Eh[2WubIOgZZN{\XO|ZXSgZZMhcGW{MjDk[Ydz[WSjdHnvckwhUUN3ME2wMlAxPDYQvF2u MlvhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh7Mkm0PFYoRjF6OUK5OFg3RC:jPh?=
MDA-MB-231 NYLDPYlTS3m2b4TvfIlkcXS7IHHzd4F6 M3jvSGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj2yN|Eh[2WubIOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvODB3ON88UU4> NXeyc4N6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi5Nlk1QDZpPkG4PVI6PDh4PD;hQi=>
A2058 NV;WWm84TnWwY4Tpc44h[XO|YYm= MYfJcohq[mm2aX;uJI9nKEi|cEmwJIlvKGi3bXHuJGEzODV6IHPlcIx{NCCHQ{WwQVAvODB5Od88UU4> MkHuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh7Mkm0PFYoRjF6OUK5OFg3RC:jPh?=
MDA-MB-231 MoPmSpVv[3Srb36gZZN{[Xl? MnHhTY5pcWKrdHnvckBw\iCKc4C5NEBqdiCqdX3hckBOTEFvTVKtNlMyKGOnbHzzJIF{e2W|c3XkJIF{KEGtdDDk[Ydz[WSjdHnvckwhUUN3ME2wMlAyPzcQvF2u MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDl{OUS4Okc,OTh7Mkm0PFY9N2F-
A2058 MVfGeY5kfGmxbjDhd5NigQ>? M3P1TWlvcGmkaYTpc44hd2ZiSIPwPVAhcW5iaIXtZY4hSTJyNUigZ4VtdHNiYYPz[ZN{\WRiYYOgRYt1KGSnZ4Lh[IF1cW:wLDDJR|UxRTBwMEK0N:69VS5? NX\YVGpiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi5Nlk1QDZpPkG4PVI6PDh4PD;hQi=>
HuH7 NXi0[3FuSW62aY\pdoFtKGG|c3H5 NYfDWJA4OyCmYYnz MoPCRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTIVx[XSrdHnzJGMhfmm{dYOg[4Vvd3S7cHWgNYIhS2:wMTDpcoZm[3SnZDDpckBpfW2jbjDIeWg4KGOnbHzzJIF{e2W|c3XkJIF{KEeDUFTIJHJPSSCxcjCxPHMhelKQQTDs[ZZmdCCjZoTldkA{KGSjeYOgZpkheVKWLWDDVkBidmGueYPpd{whTUN3ME2wMlAxOTMQvF2u M{i0SVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6OUO2NVkyLz5zOEmzOlE6OTxxYU6=
HuH7 Mne0RY51cX[rcnHsJIF{e2G7 NELmOYk{KGSjeYO= M4rIXmFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhmeGG2aYTpd{BEKH[rcoXzJIdmdm:2eYDlJFFjKEOxbkGgbY5n\WO2ZXSgbY4hcHWvYX6gTJVJPyClZXzsd{Bie3Onc4Pl[EBieyCJQWDETEBTVkFib4KgNVhUKHKUTlGgcIV3\WxiYX\0[ZIhOyCmYYnzJJNmdGWldHXkJJdqfGhiNECgcm0hUEOYLUe5OkBidmRiOECwJI5OKGKxY3XwdoV3cXJiYomgdXJVNVCFUjDhcoFtgXOrczygSWM2OD1yLkCwN|HPxE1w MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDl|NkG5NUc,OTh7M{[xPVE9N2F-
SKBR3 M1Tyd2Z2dmO2aX;uJIF{e2G7 MXTCbY5lcW6pIHHm[olvcXS7IITvJGh{eDlyIHnuJIh2dWGwIGPLRnI{KGOnbHzzMEBKSzVyPUCuNFI1|ryPLh?= M3raTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MEG3OVYzLz5zOUCxO|U3OjxxYU6=
Hep3B M{i2NWZ2dmO2aX;uJIF{e2G7 MYqzNEBucW6| MYTJcohq[mm2aX;uJI9nKGi7cH;4bYEucW6mdXPl[EBJUUZzYXzwbIEheHKxdHXpckBi[2O3bYXsZZRqd25iaX6gbJVu[W5iSHXwN2Ih[2WubIOgeJJm[XSnZDDmc5IhOzBibXnud{Bu\WG|dYLl[EBi\nSncjCxNkBpenNiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{NCCLQ{WwQVAvODV5Mt88UU4> NUSxb4hZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmwO|IzOTRpPkG5NFczOjF2PD;hQi=>
Hep3B NV\JVXRJTnWwY4Tpc44h[XO|YYm= M4DCNFE3KGi{cx?= NVj1[Gl2UW6qaXLpeIlwdiCxZjDofZBwgGmjLXnu[JVk\WRiVlXHSkBxem:2ZXnuJJNm[3KndHnvckBqdiCqdX3hckBJ\XB|QjDj[YxteyCjZoTldkAyPiCqcoOgZpkhTUyLU1GsJGlEPTB;MD6wO|k2|ryPLh?= MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTB5MkKxOEc,OTlyN{KyNVQ9N2F-
HCT116 MWjDfZRwfG:6aXPpeJkh[XO|YYm= NH21RXQ4OiCqcoO= Mn:yR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGNVOTF4IHPlcIx{KGGodHXyJFczKGi{czygTWM2OD1yLkC1O:69VS5? NF\QZoc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUKzNVg3PCd-MUmyN|E5PjR:L3G+
SKBR3 NI\IVnpEgXSxdH;4bYNqfHliYYPzZZk> NHHvbnE4OiCqcoO= NGntfW1EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUU0KUMzDj[YxteyCjZoTldkA4OiCqcoOsJGlEPTB;MD6wOVjPxE1w NEXzTHI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUKzNVg3PCd-MUmyN|E5PjR:L3G+
MCF7 MYrDfZRwfG:6aXPpeJkh[XO|YYm= NEeyelc4OiCqcoO= MVHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IEeyJIhzeyxiSVO1NF0xNjB5Md88UU4> NXvzfo52RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmyN|E5PjRpPkG5NlMyQDZ2PD;hQi=>
SKOV3 MkDoR5l1d3SxeHnjbZR6KGG|c3H5 NVKwcGF4PzJiaILz MoX2R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV2tQXjNiY3XscJMh[W[2ZYKgO|IhcHK|LDDJR|UxRTBwMUKy{txONg>? M1[yd|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MkOxPFY1Lz5zOUKzNVg3PDxxYU6=
SKBR3 M1XyfGN6fG:2b4jpZ4l1gSCjc4PhfS=> NFnzT404OiCqcoO= MVzDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTT2JTOyClZXzsd{Bi\nSncjC3NkBpenNiaX6gdJJme2WwY3Wgc4YhVlGRMTDpcohq[mm2b4Kg[Ilkd3WvYYLvcEwhUUN3ME2wMlI{|ryPLh?= MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTJ|MUi2OEc,OTl{M{G4OlQ9N2F-
MCF7 MoW3R5l1d3SxeHnjbZR6KGG|c3H5 MXW3NkBpenN? MUXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IEeyJIhzeyCrbjDwdoV{\W6lZTDv[kBPWU9zIHnubIljcXSxcjDkbYNwfW2jcn;sMEBKSzVyPUCuPFYz|ryPLh?= MkjVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl{M{G4OlQoRjF7MkOxPFY1RC:jPh?=
NCI-H596 MWDDfZRwfG:6aXPpeJkh[XO|YYm= NIn4OFM4OiCqcoO= MnfUR5l1d3SxeHnjbZR6KGGpYXnud5QhVlFyMT3k[YZq[2mnboSgbJVu[W5iTlPJMWg2QTZiY3XscJMh[W[2ZYKgO|IhcHK|LDDJR|UxRTFwMd88UU4> NH[yUlk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUKzNVg3PCd-MUmyN|E5PjR:L3G+
MDA468 NFPRdoVEgXSxdH;4bYNqfHliYYPzZZk> NHL1cYo4OiCqcoO= MlTSR5l1d3SxeHnjbZR6KGGpYXnud5QhVlFyMT3k[YZq[2mnboSgbJVu[W5iTVTBOFY5KGOnbHzzJIFnfGW{IEeyJIhzeyxiSVO1NF0yNjcQvF2u NEX1Xnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUKzNVg3PCd-MUmyN|E5PjR:L3G+
SKBR3 M2\vWGN6fG:2b4jpZ4l1gSCjc4PhfS=> M4TXU|czKGi{cx?= NYTjToMyS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW0uEUkOgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KGOnbHz0bZRmei2pbH:gZZN{[XluIFnDOVA:OC5yMkVOwG0v NWX6enplRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm0NFU2OjhpPkG5OFA2PTJ6PD;hQi=>
A549 MoTER5l1d3SxeHnjbZR6KGG|c3H5 MXW3NkBpenN? NI\vN49EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCPTR7IHPlcIx{KGGodHXyJFczKGi{czDifUBk\WyudHn0[ZIu\2yxIHHzd4F6NCCLQ{WwQVAvODZ6zszNMi=> Moj6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl2MEW1NlgoRjF7NEC1OVI5RC:jPh?=
SKOV3 NEjVNI9EgXSxdH;4bYNqfHliYYPzZZk> M3T0WVczKGi{cx?= NWfaU2w6S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW0uRVkOgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KGOnbHz0bZRmei2pbH:gZZN{[XluIFnDOVA:OC5{Mt88UU4> MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTRyNUWyPEc,OTl2MEW1Nlg9N2F-
MCF7 MV7DfZRwfG:6aXPpeJkh[XO|YYm= MkH4O|IhcHK| NEjxOXFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOS0Z5IHPlcIx{KGGodHXyJFczKGi{czDifUBk\WyudHn0[ZIu\2yxIHHzd4F6NCCLQ{WwQVAvOjQQvF2u NILTTFU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUSwOVUzQCd-MUm0NFU2Ojh:L3G+
CCRF-CEM MkDCR5l1d3SxeHnjbZR6KGG|c3H5 M{\UeVczKGi{cx?= MorYR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gR2NTTi2FRV2gZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KGOnbHz0bZRmei17NjDhdZVmd3W|IH;u[UB{d2y3dHnvckBie3OjeTygTWM2OD1yLkW0{txONg>? NWfJcJpHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm0NFU2OjhpPkG5OFA2PTJ6PD;hQi=>
CCRF-CEM NVHPc3ZKS3m2b4TvfIlkcXS7IHHzd4F6 MVS3NkBpenN? M2XtN2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJJBi[2yrdHH4[YwuemW|aYP0ZY51KEOFUl[tR2VOKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDj[YxtfGm2ZYKtPVYh[XG3ZX;1d{BwdmVic3;seZRqd25iYYPzZZktKEmFNUC9Nk42|ryPLh?= NIrFeHQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUSwOVUzQCd-MUm0NFU2Ojh:L3G+
Hep3B NH\a[5lHfW6ldHnvckBie3OjeR?= MUizNEBucW6| M1y0WWlvcGmkaYTpc44hd2ZiaInwc5hq[S2rbnT1Z4VlKEiLRkHhcJBp[SCycn;0[YlvKGGlY4XteYxifGmxbjDpckBpfW2jbjDI[ZA{SiClZXzsd{B1emWjdHXkJIZweiB|MDDtbY5{KG2nYYP1doVlKGGodHXyJFEzKGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXNuIFnDOVA:OC5yNUhOwG0v NYXHeFZTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC0Olk5QDdpPkKwOFY6QDh5PD;hQi=>
Hep3B MnPySpVv[3Srb36gZZN{[Xl? NFnMPVgyPiCqcoO= MnTETY5pcWKrdHnvckBw\iCqeYDvfIliNWmwZIXj[YQhXkWJRjDwdo91\WmwIIPlZ5JmfGmxbjDpckBpfW2jbjDI[ZA{SiClZXzsd{Bi\nSncjCxOkBpenNiYomgSWxKW0FuIFnDOVA:OC5yN{pOwG0v MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODR4OUi4O{c,OjB2Nkm4PFc9N2F-
HCT116 NX;NepdmS3m2b4TvfIlkcXS7IHHzd4F6 NF6zNZJEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJS1RzMU[gZ4VtdHNiYomgRYxidWG{IHLseYUh[XO|YYmsJGlEPTB;MD6wOe69VS5? MknFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB4NkK1N|QoRjJyNk[yOVM1RC:jPh?=
NCI-H1299 Mm\wSpVv[3Srb36gZZN{[Xl? MXeyOEBpenN? NWPm[pNkUW6qaXLpeIlwdiCxZjDoeY1idiCKU2C5NEBqdiCqdX3hckBPS0lvSEGyPVkh[2WubIOgZZN{\XO|ZXSgZZMhSWu2IHTl[5Ji\GG2aX;uJIFnfGW{IEK0JIhzeyCkeTDseY1qdmW6IHHzd4F6NCCLQ{WwQVAvOc7:TT6= NV7ZWJdORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0N|g2PDFpPkKxOFM5PTRzPD;hQi=>
LN229-Lux NYH1d3c4TnWwY4Tpc44h[XO|YYm= M17MflIvPSC2bzCxNEB2VQ>? MkjmNUBpeg>? M4HtbGlvcGmkaYTpc44hd2ZibIXjbYZmemG|ZTDhZ5Rqfmm2eTDpckBpfW2jbjDMUlIzQS2OdYigZ4VtdHNiYYSgNk42KHSxIEGwJJVOKGmwY4XiZZRm\CCob4KgNUBpeiC3bnTldkBvd3Kvb4jpZUBnd2yub4fl[EBjgSB{NDDodpMhfW6mZYKgbJlxd3irYTDifUBz\XCxcoTldkBo\W6nIHHzd4F6 M3\HSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{N{S2Nlc1Lz5{Mke0OlI4PDxxYU6=
MCF7 M1rSZmFvfGmycn;sbYZmemG2aY\lJIF{e2G7 NIXmXXQ1QCCqcoO= MVfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkegZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iClZXzsJJZq[WKrbHn0fUBi\nSncjC0PEBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUCuN|nPxE1w NWPWZ3JuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1PFI1PzdpPkK0OVgzPDd5PD;hQi=>
HCT116 MYjBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? MYi0PEBpenN? MW\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFVEGxOkBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHPlcIwhfmmjYnnsbZR6KGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZktKEmFNUC9NE44QM7:TT6= M4XTVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUiyOFc4Lz5{NEW4NlQ4PzxxYU6=
SKBR3 NUm2RWRlSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= MUO0PEBpenN? NVnleG5vSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTT2JTOyClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJINmdGxidnnhZoltcXS7IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OS5|NN88UU4> MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV6MkS3O{c,OjR3OEK0O|c9N2F-
A231 NXuzdYRUSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= NWTC[GhiPDhiaILz M1jsVmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUKzNUBk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTBwMUhOwG0v NIS0Xoc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe2N|I3OSd-MkS3OlMzPjF:L3G+
MCF7 NWS0TVg6SW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= NHPhXJU1QCCqcoO= NFfHTnVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3DSlch[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1yLklOwG0v NVLKU3p{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3OlMzPjFpPkK0O|Y{OjZzPD;hQi=>
HCT116 MoDRRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MmfyOFghcHK| NYiyeIMySW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[W[2ZYKgOFghcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2xMlIy|ryPLh?= NWf2c|dORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3OlMzPjFpPkK0O|Y{OjZzPD;hQi=>
SKBR3 M4HmNmFvfGmycn;sbYZmemG2aY\lJIF{e2G7 NVPaNIkxPDhiaILz NGe5UoFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPLRnI{KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;Mz6xNe69VS5? NVS1TZBlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3OlMzPjFpPkK0O|Y{OjZzPD;hQi=>
NCI-H1299 MXzGeY5kfGmxbjDhd5NigQ>? Ml[xNVIhcHK| MWXS[YR2[3Srb36gbY4hd3i7Z3XuJINwdnO3bYD0bY9vKHKjdHWgbY4hcHWvYX6gUmNKNUhzMkm5JINmdGy|IHnuZ5Vj[XSnZDDmc5IhOTJiaILz MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTN6M{mxOUc,OjV|OEO5NVU9N2F-
PC9 MmLlR5l1d3SxeHnjbZR6KGG|c3H5 Mni0O|IhcHK| NXXxdG94S3m2b4TvfIlkcXS7IHHnZYlve3RiSFfGMYlv\HWlZXSg[ZJtd3SrbnniMZJme2m|dHHueEBpfW2jbjDQR|kh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDj[YxtKGe{b4f0bEBi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUCuNFHPxE1w NUH5UIw3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[4OFQ3QDlpPkK2PFQ1Pjh7PD;hQi=>
Ma1 NHHkTJFEgXSxdH;4bYNqfHliYYPzZZk> MmG5O|IhcHK| Mnj0R5l1d3SxeHnjbZR6KGGpYXnud5QhUEeILXnu[JVk\WRiZYLsc5RqdmmkLYLld4l{fGGwdDDoeY1idiCPYUGgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iClZXzsJIdzd3e2aDDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTBwMEJOwG0v MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjh2NE[4PUc,OjZ6NES2PFk9N2F-
SKBR3 MWjGeY5kfGmxbjDhd5NigQ>? MXfJcohq[mm2aX;uJI9nKEi|cEmwJIlvKGi3bXHuJHNMSlJ|IHPlcIx{NCCLQ{WwQVAvODJ2zszNMi=> NHHrNIc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nki0OFY5QSd-Mk[4OFQ3QDl:L3G+
HeLa MUDGeY5kfGmxbjDhd5NigQ>? MXKxNEB2VQ>? MYe2JIhzew>? NXXtW2FzUW6qaXLpeIlwdiCxZjDIV3A6OCCrbjDoeY1idiCKZVzhJINmdGy|IHHzd4V{e2WmIHHzJIlv\HWldHnvckBw\iClaHuxJIRm\3KjZHH0bY9vKGG2IEGwJJVOKGGodHXyJFYhcHK|IHL5JHdme3Sncn6gZoxwfCCvZYToc4Q> M2n2eVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OEG2OFQ6Lz5{OEixOlQ1QTxxYU6=
HeLa M3zSTGZ2dmO2aX;uJIF{e2G7 NVPuS3FuOTBidV2= NXTMdVBrPiCqcoO= M1jWfGlvcGmkaYTpc44hd2ZiSGPQPVAhcW5iaIXtZY4hUGWOYTDj[YxteyCjc4Pld5Nm\CCjczDpcoR2[3Srb36gc4YhSWu2IHTl[5Ji\GG2aX;uJIF1KDFyIIXNJIFnfGW{IE[gbJJ{KGK7IGfld5Rmem5iYnzveEBu\XSqb3S= NXXBbpZuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4NVY1PDlpPkK4PFE3PDR7PD;hQi=>
HeLa MlH5SpVv[3Srb36gZZN{[Xl? MX:xNEB2VQ>? MWS2JIhzew>? NF3o[IdKdmirYnn0bY9vKG:oIFjTVFkxKGmwIHj1cYFvKEinTHGgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5lfWO2aX;uJI9nKEiVUEewJJBzd3SnaX6g[ZhxemW|c3nvckBifCBzMDD1UUBi\nSncjC2JIhzeyCkeTDX[ZN1\XKwIHLsc5QhdWW2aH;k M4LHcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OEG2OFQ6Lz5{OEixOlQ1QTxxYU6=
PC3 MmrhSpVv[3Srb36gZZN{[Xl? M3nrO|ExKHWP M4nF[VYhcHK| MYnJcohq[mm2aX;uJI9nKEiVUEmwJIlvKGi3bXHuJHBEOyClZXzsd{Bie3Onc4Pl[EBieyCrbnT1Z5Rqd25ib3[gZ4hsOSCmZXfyZYRifGmxbjDheEAyOCC3TTDh[pRmeiB4IHjyd{BjgSCZZYP0[ZJvKGKub4SgcYV1cG:m MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDhzNkS0PUc,Ojh6MU[0OFk9N2F-
PC3 MX7GeY5kfGmxbjDhd5NigQ>? NHnHcnEyOCC3TR?= M1uxTFYhcHK| MUHJcohq[mm2aX;uJI9nKEiVUEmwJIlvKGi3bXHuJHBEOyClZXzsd{Bie3Onc4Pl[EBieyCrbnT1Z5Rqd25ib3[gRYt1KGSnZ4Lh[IF1cW:wIHH0JFExKHWPIHHmeIVzKDZiaILzJIJ6KFenc4Tldo4h[myxdDDt[ZRpd2R? MkXTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6MU[0OFkoRjJ6OEG2OFQ6RC:jPh?=
PC3 MWjGeY5kfGmxbjDhd5NigQ>? NUTTdll{OTBidV2= NUPyXY9jPiCqcoO= NHHIUI1KdmirYnn0bY9vKG:oIFjTVFkxKGmwIHj1cYFvKFCFMzDj[YxteyCjc4Pld5Nm\CCjczDpcoR2[3Srb36gc4YhUFOSN{CgdJJwfGWrbjDlfJBz\XO|aX;uJIF1KDFyIIXNJIFnfGW{IE[gbJJ{KGK7IGfld5Rmem5iYnzveEBu\XSqb3S= NWPKSZZ7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4NVY1PDlpPkK4PFE3PDR7PD;hQi=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
HSP90 / HSP70 ; 

PubMed: 28915605     


Western blot analysis showing dose-dependent elevation of Hsp70 and HSP90 levels in AGS cells by 17-DMAG.

p-Akt / Survivin / MMP2 ; 

PubMed: 28915605     


Western blot analysis showing the dose-dependent reduction of the expression of HSP90 client proteins, such as p-Akt, survivin, and MMP2 by 17-DMAG.

PARP / Cleaved caspase-3 / Cleaved caspase-8 / Cleaved caspase-9 / PUMA ; 

PubMed: 28915605     


(C-D) 17-DMAG effects on the expression of apoptotic proteins (PARP, c-caspase 3, c-caspase-8, c-caspase-9, and PUMA) in AGS cells. Western blot analyses indicate that 17-DMAG significantly increased the expression of apoptotic proteins in AGS cells in a dose- (C) and time- (D) dependent manner (P < 0.05).

p-ALK / ALK / p-Akt / Akt / p-ERK / ERK ; 

PubMed: 26219569     


Modulation of ALK signaling in parental and 17-DMAG-resistant cells. Cells were treated with the indicated concentrations of 17-DMAG or AUY922 for 6 h. The molecules of ALK-related signaling activity were detected by western blot analysis.

α-Tax / α-IKKα / α-IKKβ/ α-NEMO / α-TBK1 / α-p65 / α-p50 ; 

PubMed: 24109220     


C8166, MT-2, and MT-4 cells were treated with 17-DMAG as indicated, and cell lysates were subjected to immunoblotting with the indicated antibodies.

28915605 26219569 24109220
Growth inhibition assay
Cell proliferation ; 

PubMed: 28915605     


Proliferation assay of AGS cells treated with graded concentrations of 17-DMAG for 24 h or 48 h. 17-DMAG resulted in significant dose- and time-dependent reduction of AGS cell proliferation (P < 0.05)

28915605
体内研究 17-DMAG按5 mg/kg 或 25 mg/kg处理,每周三次,显著降低 TMK-1 移植瘤生长,通过显著降低血管面积和增殖肿瘤细胞数。[2]与抑制FAK信号一致,17-DMAG 按 25 mg/kg剂量处理小鼠,每周三次,显著抑制肿瘤生长,及ME180 和SiHa 移植瘤的转移。[4]17-DMAG 按10 mg/kg 剂量处理TCL1-SCID移植鼠模型,处理16天,显著降低白细胞数,且延长寿命。[5]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
- 合并

荧光偏振(FP)为基础的竞争性结合实验:

实验使用氟化硼亚甲基二吡咯(BODIPY)标记的Geldanamycin类似物 (BODIPY-AG) 作为探针,根据探针与蛋白结合情况,测定荧光偏振。从 HeLa细胞中分离活性人类Hsp90 蛋白 (α + β 亚型)。 BODIPY-AG 溶液在FP 实验 buffer (20 mM HEPES-KOH, pH 7.3, 1.0 mM EDTA, 100 mM KCl, 5.0 mM MgCl2, 0.01% NP-40, 0.1 mg/mL 新鲜牛γ-球蛋白 (BGG), 1.0 mM 新鲜DTT,和蛋白酶抑制剂,溶于)中新鲜制备。通过10 μL每组含 BODIPY-AG 和Hsp90的溶液,与连续稀释的 17-DMAG(在 FP 实验 buffer中新鲜制备)混合,而获得竞争性曲线。终浓度为10 nM BODIPY-AG, 40 或 60 nM Hsp90,不同浓度 17-DMAG (0.10 nM-10 μM), 和 ≤0.25% DMSO 在384孔板中混合。30oC下温育3小时后, 在EnVision 2100多标记酶标仪上测定荧光 各向异性(γEx = 485 nm, γEm = 535 nm) 。从竞争曲线中获得17-DMAG的IC50值。
细胞实验:[5]
- 合并
  • Cell lines: 慢性淋巴细胞白血病(CLL)
  • Concentrations: 溶于DMSO,终浓度为~1 μM
  • Incubation Time: 24, 或48小时
  • Method: 使用不同浓度17-DMAG 处理细胞24,或48小时。为了测量毒性, 加如MTT试剂,实验板再温育24小时,然后使用分光光度法测量。通过膜联蛋白 V-异硫氰酸荧光素和碘化丙啶(PI)染色测定凋亡。
    (Only for Reference)
动物实验:[5]
- 合并
  • Animal Models: 移植TCL1 白血病细胞的SCID小鼠
  • Dosages: 10 mg/kg
  • Administration: 腹腔注射,每周5次
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 131 mg/mL (200.54 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
1% DMSO+30% polyethylene glycol+1% Tween 80
30 mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 653.21
化学式

C32H48N4O8•HCl

CAS号 467214-21-7
储存条件 粉状
溶于溶剂
别名 NSC 707545,BMS 826476 HCl,KOS 1022

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT00780000 Terminated Drug: Alvespimycin Breast Cancer Bristol-Myers Squibb April 2008 Phase 2
NCT00248521 Unknown status Drug: alvespimycin hydrochloride Unspecified Adult Solid Tumor Protocol Specific Institute of Cancer Research United Kingdom|National Cancer Institute (NCI) October 2005 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

HSP (HSP90) Signaling Pathway Map

HSP (HSP90) Inhibitors with Unique Features

相关HSP (HSP90)产品

Tags: 购买Alvespimycin (17-DMAG) HCl | Alvespimycin (17-DMAG) HCl供应商 | 采购Alvespimycin (17-DMAG) HCl | Alvespimycin (17-DMAG) HCl价格 | Alvespimycin (17-DMAG) HCl生产 | 订购Alvespimycin (17-DMAG) HCl | Alvespimycin (17-DMAG) HCl代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID